Quotient Clinical expands into USA through acquisition of SeaView Research, the specialist clinical pharmacology business

Quotient Clinical announces that it has acquired SeaView Research, expanding its operations into the USA. The acquisition combines Quotient and SeaView’s complementary customer portfolios, and strengthens the early phase clinical experience of the combined business, enabling the company to deliver a broader set of services.

SeaView is an expert clinical pharmacology business founded in 1995, with 160 employees across two clinical pharmacology units located in Miami and Jacksonville, Florida, and a combined bed capacity of 320. Each of the two facilities is capable of undertaking complex clinical research studies including first-in-human investigations.

Mark Egerton, Chief Executive Officer, Quotient, said: “Establishing an operational footprint in the US is an important milestone in the development of our business. We can now offer our customers the option to undertake their early phase clinical research either in the UK or the USA, and the acquisition of SeaView is a key component of our plan to replicate our Translational Pharmaceutics platform in the USA.”

Quotient’s proprietary and unique Translational Pharmaceutics platform integrates clinical testing with formulation development and real-time GMP manufacturing. This innovative approach is increasingly recognised in the industry for reducing clinical development timelines and cutting associated costs. Over 100 leading pharmaceutical and biotech companies have chosen Translational Pharmaceutics to accelerate the development of their products for a variety of indications and routes of delivery.

Stuart Harris and Celina Alvarez, co-founders of SeaView, said: “We are excited to join forces with Quotient and are looking forward to working together to continue growing the business. The combination of the Quotient and SeaView businesses enables us to deliver full service support to our customers, and the market potential for Translational Pharmaceutics in the USA is significant.”